Abstract
There are three major categories of transplant melanoma: pretransplant, posttransplant, and donor-derived melanoma. Dermatologists are involved in screening transplant candidates to help identify a history of pretransplant melanoma or other high-risk factors for posttransplant melanoma. For those with a history of pretransplant melanoma, AJCC melanoma staging should help guide wait times prior to transplantation to ensure ethical allocation of a scarce resource. The incidence of posttransplant malignant melanoma is estimated to be three to five times higher than the general public and is associated with a worse prognosis. While donor-derived melanoma is rare in transplant patients, it has been reported as the most commonly transmitted tumor-causing distant metastasis and is associated with a poor overall survival.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AJCC:
-
American Joint Committee on Cancer
- AKs:
-
Actinic keratosis
- FISH:
-
Fluorescent in situ hybridization
- HLA:
-
Human leukocyte antigen
- IHC:
-
Immunohistochemistry
- ITSC:
-
International Transplant Skin Cancer Collaborative
- NCCN:
-
National Comprehensive Cancer Network
- NIH:
-
National Institutes of Health
- NMSC:
-
Nonmelanoma skin cancer
- OPTN:
-
Organ Procurement and Transplantation Network
- OTRs:
-
Organ transplant recipients
- PCR:
-
Polymerase chain reaction
- SCOPE:
-
Skin Care in Organ Transplant Patients, Europe
- SRTR:
-
Scientific Registry of Transplant Recipients
- USA:
-
United States of America
References
Ali FR, Lear JT. Melanoma in organ transplant recipients: incidence, outcomes, and management considerations. J Skin Cancer. 2012, epub.
Bajaj NS, Watt C, Hadjiliadis D, et al. Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection. Transpl Int. 2010;23(7):e26–31.
Berg, Otley. The reference is Skin cancer in organ transplant recipients. Epidemiology, pathogenesis and management. J Am Acad Dermatol. 2002;47(1):1–17.
Birkeland SA, Storm HH. Risks for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74:1409–13.
Brewer JD, Christenson LJ, Weaver AL, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol. 2011;147(7):790–6.
Chen KT, Olszanski A, Farma JM. Donor transmission of melanoma following renal transplant. Case Rep Transplant epub 2012. http://dx.doi.org/10.1155/2012/764019.
Colegio OR, Proby CM, Bordeaux JS, McGregor JM, Melanoma Working Group of the International Transplant Skin Cancer C, Skin Care in Organ Transplant Patients E. Prognosis of pretransplant melanoma. Am J Transplant. 2009;9(4):862.
Dapprich DC, Weenig RH, Rohlinger AL, Weaver AL, et al. Outcomes of melanoma in recipients of solid organ transplantation. J Am Acad Dermatol. 2008;59:405–17.
Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, et al. Spectrum of cancer risk among US solid organ transplant recipients: the transplant cancer match study. JAMA. 2011;306(17):1891–901.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–91.
Hartevelt MM, Bavenick JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation. 1990;49:506–9.
Hollenbeak CS, Todd MM, Billingsley EM, et al. Increased incidence of melanoma in renal transplant recipients. Cancer. 2004;104:1962–7.
Ismail F, Mitchell L, Casabonne D, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol. 2006;155:916–25.
Jensen P, Hansen S, Moller B, Leivestad T, Pfefer P, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–86.
Le Mire L, Hollowood K, Gray D, et al. Melanomas in renal transplant recipients. Br J Dermatol. 2006;154(3):472–7.
Martin DC, Rubini M, Rosen VJ. Cadaveric renal homotransplantations with inadvertent transplantation of cancer. JAMA. 1965;192:32.
Matin RN, Mesher D, Proby CM, McGregor JM, et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant. 2008;8:1891–900.
McCarter MD, Baumgartner J, Escobar GA, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007;14(10):2854–60.
Mihalis EL, Wysong A, Boscardin WJ, et al. Factors affecting sunscreen use and sun avoidance in a US national sample of organ transplant recipients. Br J Dermatol. 2013;168(2):346–53.
Morris-Stiff G, Steel A, Savage P, Devlin J, et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant. 2004;4:444–6.
Multigonda T, Levender MM, O’Neill JL, West CE, et al. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single and multicenter retrospective studies from 2006 to 2010. Dermatol Surg. 2013;39:345–64.
Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: OPTN/SRTR 2011 Annual Data Report. Rockville: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012.
Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154(3):395–400.
Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61:274–8.
Scanlon EF, Hawkins RA, Fox WW, Smith WS. Fatal homotransplanted melanoma: a case report. Cancer. 1965;13:782–9.
Servilla KS, Burnham DK, Daynes RA. Ability of cyclosporine to promote the growth of transplanted ultraviolet radiation-induced tumors in mice. Transplantation. 1987;44:291–5.
Sheil AG. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc. 1992;24:1275–9.
Suranyi MG, Hogan PG, Falk MC, et al. Advanced donor-origin melanoma in a renal transplant patient. Transplantation. 1998;66:655.
Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4 + CD25+ regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444–53.
Wilson RN, Hager EB, Hampers CL, et al. Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med. 1968;278:479.
Younis FM, Fernando ON, Sweny P, et al. Malignant melanoma in a patient with a renal transplant. Lancet. 1980;2:1141.
Zwald FO, Christenson LJ, Billingsley EM, et al. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10(5):1297–304.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wysong, A., Soon, S.L. (2015). Update in Melanoma in Organ Transplant Patients. In: Zwald, F., Brown, M. (eds) Advances in Transplant Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-12445-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-12445-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12444-5
Online ISBN: 978-3-319-12445-2
eBook Packages: MedicineMedicine (R0)